Kaival Brands Q1 revenue plunges 93% to $2.8M; net loss $2.8M; FDA stay granted

Kaival Brands Innovations Group, Inc.

Revenue $2.8M vs $37.4M YoY, down 93% due to FDA MDO and competition.
Net loss $2.8M ($0.09 loss per share) vs net income $0.3M ($0.01 EPS) YoY.
Gross loss $700K (negative 24.3% margin) vs $4.8M gross profit (11.2% margin) YoY.
Judicial stay of FDA Marketing Denial Order granted Feb 1, 2022; expects to resume flavored BIDI Stick sales.
Regained Nasdaq minimum bid price compliance on Feb 18, 2022.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.